SK Biopharmaceuticals Co., Ltd.
326030
株式のランク
#4040
SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the... SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the research, identification, and development of novel therapies for central nervous system (CNS) disorders. Their product portfolio features Cenobamate, indicated for the treatment of epilepsy, and Solriamfetol, which addresses excessive daytime sleepiness experienced in conditions like narcolepsy or obstructive sleep apnea. The company's robust clinical pipeline includes Carisbamate, currently in Phase 1b/2 trials for Lennox-Gastaut syndrome, and Relenopride, advancing through Phase 2 for a rare neurological disease. Additionally, they have several candidates in Phase 1 development: SKL13865 for attention deficit/hyperactivity disorder (ADHD), SKL20540 for schizophrenia, SKL-PSY for bipolar disorder, and SKL24741, another potential treatment for epilepsy. Founded in 2011, the company is headquartered in Seongnam, South Korea, and functions as a subsidiary of SK Inc.
株価
$51.65
時価総額
$4.05B
変化（1日）
0.27%
変化（1年）
-30.95%
国
KR
取引 SK Biopharmaceuticals Co., Ltd. (326030)
カテゴリー
Healthcare
SK Biopharmaceuticals Co., Ltd.（326030）の発行済株式数
June 2026 時点の発行済株式数 78.31M
SK Biopharmaceuticals Co., Ltd. の最新の財務報告および株価によると、現在の発行済株式数は 78.31M です。December 2024 の終わりには、同社は 78.31M 株の発行済株式 を有していました。発行済株式数は、通常、株式分割や自社株買いによって影響を受けます。
SK Biopharmaceuticals Co., Ltd.（326030）の発行済株式数の履歴（2011 ～ 2026）
各年末時点の発行済株式数
| 年 | 発行済株式数 | 変化 |
|---|---|---|
| 2026 (TTM) | 78.31M | -100.00% |
| 2025 | 0.00 | -100.00% |
| 2024 | 78.31M | 0.00% |
| 2023 | 78.31M | 0.00% |
| 2022 | 78.31M | 0.00% |
| 2021 | 78.31M | 9.12% |
| 2020 | 71.77M | 10.41% |
| 2019 | 65.00M | 4.44% |
| 2018 | 62.23M | 24.47% |
| 2017 | 50.00M | -0.04% |
| 2016 | 50.02M | 0.04% |
| 2015 | 50.00M | 1.08% |
| 2014 | 49.46M | 23.66% |
| 2013 | 40.00M | -0.03% |
| 2012 | 40.01M | 0.11% |
| 2011 | 39.97M | 0.00% |
類似企業や競合他社の発行済株式数
| 企業 | 発行済株式数 | 差 | 国 |
|---|---|---|---|
| 253.90M | 224.21% |
US
|
|
| 396.00M | 405.66% |
US
|
|
| 478.91M | 511.54% |
AU
|
|
| 62.19M | -20.59% |
NL
|
|
| - | - |
CH
|
